Wyeth presents bazedoxifene and conjugated oestrogens data

Wyeth Pharmaceuticals, a segment of Wyeth, has this week announced the results of two phase III studies of bazedoxifene and conjugated oestrogens to the North American Menopause Society annual Meeting.

The trial results showed that the compounds reduced the severity of hot flashes recorded in postmenopausal women by up to 80 per cent, in addition to improving symptoms of vulvar and vaginal atrophy.

Furthermore, additional trial data showed that patients receiving bazedoxifene and conjugated oestrogens exhibited improved menopause-related quality of life and reduced sleep disturbances.

Ginger Constantine, vice-president of women’s health care and bone repair at Wyeth Pharmaceuticals, said: “The pairing of bazedoxifene, a selective oestrogen receptor modulator, or SERM, with conjugated oestrogens may lead to a new class of menopausal therapy called tissue selective estrogen complex, or TSEC.”

She added that the TSECs combine the benefits of SERMs with those of oestrogens to form a distinct clinical profile which can potentially treat symptoms of menopause, including relief of hot flashes and bone and uterine protection.

Last month, Wyeth presented positive three-year clinical trial data of bazedoxifene to the annual meeting of the American Society for Bone and Mineral Research, with the compound reducing the relative risk of new vertebral fractures by 42 per cent and 37 per cent at 20 mg and 40 mg doses respectively.